🌟 IVA 2026 nominations are open! 🌟

This year, every shortlisted volunteer will be celebrated as a winner at our afternoon tea event on 29/05/2026. Know someone who deserves a shout out?

Nominate them here 👉 www.volunteereastlothian.org.uk/all-news/ins...

#VCEL #IVAEastLothian #Volunteering

FDA approves new Vericel cell therapy plant to expand cartilage repair Burlington, Mass. facility starts MACI production in Q2 2026, expanding Vericel’s cell therapy capacity and enabling potential sales outside the U.S.

#VCEL Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility

www.stocktitan.net/news/VCEL/vericel-announ...

Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results Vericel (NASDAQ:VCEL) reported strong fourth-quarter and full-year 2025 results: total revenue $276.3M, MACI revenue $239.5M (+21% YoY), and record Q4 gross margin of 79%. Full-year adjusted EBITDA rose to $70.9M (26% margin) and the company holds approximately $200M cash with no debt. Management provided 2026 guidance: total revenue of $316–$326M, MACI revenue of $280–$286M, and ~75% gross margin.Q4 highlights included record MACI implants and salesforce expansion; the company remains on track for commercial manufacturing and a UK MHRA submission in 2026.

#VCEL Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results

www.stocktitan.net/news/VCEL/vericel-report...

🚀 Our February 2026 Funding Update is now live!
👉 Read the full update here: wwww.volunteereastlothian.org.uk/all-news/vcel-monthly-funding-update-february-2026
If you’re applying for funding remember - VCEL is here to help! 💡
#EastLothian #FundingOpportunities #ThirdSector #VCEL #CommunitySupport

Vericel Announces Preliminary 2025 Financial Results and Business Updates Vericel (NASDAQ:VCEL) reported preliminary, unaudited 2025 results: total revenue ~$276 million comprising MACI revenue $239.5 million and Burn Care $36.5 million. Gross margin is expected at 74% and adjusted EBITDA margin at 26%. The company expects GAAP net income for the second consecutive year and ended the period with $200 million cash and investments and no debt. Q4 marks the highest quarterly counts since launch for MACI implants, implanting surgeons, surgeons taking biopsies, and MACI biopsies, with MACI revenue growth of 20%+ for a third straight year. Completed MACI sales force expansion, >900 MACI Arthro trained surgeons, initiated the MACI Ankle MASCOT study, and remain on track to begin commercial manufacturing at a new facility in 2026.

#VCEL Vericel Announces Preliminary 2025 Financial Results and Business Updates

www.stocktitan.net/news/VCEL/vericel-announ...

Vericel Reports Third Quarter 2025 Financial Results Vericel (NASDAQ:VCEL) reported record third-quarter 2025 results with $67.5M total revenue and MACI revenue up 25% to $55.7M. Gross margin was 73.5%, net income was $5.1M (or $0.10 diluted EPS), and non-GAAP adjusted EBITDA rose 69% to $17.0M (25% of revenue). Operating cash flow was a record $22.1M. Burn care revenue totaled $11.8M (Epicel $10.4M; NexoBrid $1.5M) with NexoBrid quarterly revenue up 38% year-over-year. Cash and investments totaled $185M with no debt. The company reaffirmed 2025 guidance of $272–$276M total revenue and ~74% gross margin.

#VCEL Vericel Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/VCEL/vericel-report...

Apply now! Communities Mental Health & Wellbeing Fund (Year 5) closes 14 Nov @ 11:59pm.

💬 Join our Q&A session on 6 Nov, 10:30–11:30am to get support and ask questions.

👉 vcel.tfaforms.net/99?eventid=a...

#VCEL #WellbeingFund #EastLothian #CommunityFunding

One Council Partnership Fund 2026/27 – Webinar Summary and Application Support — Volunteer Centre East Lothian — VCEL Support toolkit, webinar summary, and key resources available to help East Lothian groups apply for funding.

One Council Partnership Fund 2026/27 – Apply by 30 Sept!
Support toolkit, webinar summary, and key resources available to help East Lothian groups apply for funding.
👉 www.volunteereastlothian.org.uk/all-news/one...
#EastLothian #CommunityFunding #VCEL

Communities Mental Health & Wellbeing Fund for Adults – Year 5 Now Open! — Volunteer Centre East Lothian — VCEL Applications now open for the Communities Mental Health & Wellbeing Fund (Year 5–6)! Grants up to £50,000 available for community-led mental health projects in East Lothian.

🌟 Applications now open!
Communities Mental Health & Wellbeing Fund (East Lothian) – up to £50k for local projects.

📅 Apply by 14 Nov
🔗 www.volunteereastlothian.org.uk/all-news/communities-mental-health-amp-wellbeing-fund-for-adults-year-5-now-open

#EastLothian #MentalHealth #VCEL

VCEL Monthly Funding Update | August 2025 — Volunteer Centre East Lothian — VCEL Welcome to the latest funding update from Volunteer Centre East Lothian.

🌟 Welcome to the latest funding update from Volunteer Centre East Lothian

#VCEL #CommunitySupport #fundingupdate

www.volunteereastlothian.org.uk/all-news/vcel-monthly-funding-update-august-2025

Vericel Reports Second Quarter 2025 Financial Results Vericel (NASDAQ:VCEL) reported strong Q2 2025 financial results, with total revenue growing 20% to $63.2 million. The company's flagship product MACI saw revenue growth of 21% to $53.5 million, while Burn Care revenue reached $9.8 million. Notable achievements include a gross margin increase of 400+ basis points to 74% and adjusted EBITDA growth of 112% to $13.4 million.Key operational highlights include training approximately 600 MACI Arthro surgeons, receiving FDA IND clearance for the MACI Ankle clinical study, and achieving the highest number of Epicel biopsies since 2023. The company maintains a strong financial position with $164 million in cash and investments and no debt, while reaffirming its 2025 guidance for MACI revenue growth in the low 20% range.

#VCEL Vericel Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/VCEL/vericel-report...

Vericel Sees Record Q1, Bullish on Second Half as MACI Arthro Gains Traction Surgeon adoption, biopsy growth, and burn care recovery fuel raised margin outlook and strong Q2 forecast Vericel Corporation (NASDAQ: VCEL) posted strong fi

#VCEL
Vericel Corp posted a record Q1, reaffirmed revenue guidance, and raised profitability targets for 2025. Strong biopsy trends, expanding surgeon adoption, and burn care momentum are fueling bullish second-half expectations.
Read the full PRISM breakdown: prismmarketview.com/vericel-sees...

Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance Vericel Corporation (NASDAQ: VCEL) reported strong Q1 2025 financial results, with total revenue reaching $52.6 million. The company's flagship product MACI achieved record Q1 revenue of $46.3 million, representing 15% growth year-over-year. Burn Care revenue totaled $6.3 million, including $5.0 million from Epicel and $1.3 million from NexoBrid. Key financial metrics include a gross margin of 69%, net loss of $11.2 million ($0.23 per share), and adjusted EBITDA of $3.2 million. The company maintains a strong financial position with $162 million in cash and investments and no debt. Notably, approximately 400 MACI Arthro surgeons have been trained to date, showing over 30% biopsy growth. Vericel reaffirmed its 2025 revenue growth guidance of 20-23% and raised profitability guidance, projecting gross margin of 74% and adjusted EBITDA margin of 26%. Q2 2025 total revenue growth is expected to be 22-25%.

#VCEL Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

www.stocktitan.net/news/VCEL/vericel-report...

Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results Vericel (NASDAQ:VCEL) reported strong financial results for Q4 and full-year 2024. The company achieved 20% total revenue growth to $237.2 million for the full year, with MACI revenue up 20% to $197.3 million and Burn Care revenue growing 22% to $39.9 million.Q4 highlights include total net revenue of $75.4 million, record gross margin of 78%, and net income of $19.8 million. The company reported strong MACI Arthro launch indicators with approximately 250 surgeons trained. Cash position stands at $167 million with no debt.For 2025, Vericel projects revenue growth of 20-23%, with gross margin expected at 73-74%. The company also updated its mid-term profitability targets, expecting gross margin in the high-70% range and adjusted EBITDA margin in the high-30% range by 2029.

#VCEL Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results

www.stocktitan.net/news/VCEL/vericel-report...

Vericel Hits Record Q4 Results with 20% Growth, Sets Ambitious 2025 Revenue Targets Vericel achieves strong 2024 performance with $237.5M revenue, record MACI implants, and 77% gross margin. Company projects 20-23% growth for 2025 with enhanced profitability targets.

#VCEL Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets

www.stocktitan.net/news/VCEL/vericel-announ...